Pharmaceuticals

Advanced CDMO Platforms Accelerating Development Timelines in the Biologics Manufacturing Market

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Biologics Manufacturing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The biologics manufacturing market has experienced significant expansion in its size over recent years. Its valuation is projected to increase from $42.04 billion in 2025 to $50.69 billion by 2026, reflecting a compound annual growth rate (CAGR) of 20.6%. This historic growth can be primarily attributed to factors such as the broader development of recombinant protein therapeutics, the initial adoption of mammalian cell culture systems, an increase in vaccine manufacturing capacity, the growing trend of outsourcing biologics production, and innovations in purification technologies.

The biologics manufacturing market size is anticipated to undergo significant growth in the upcoming years. It is projected to attain $106.08 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 20.3%. This expansion during the forecast period is primarily driven by increasing demand for personalized biologics, rising investments in flexible manufacturing platforms, expansion of biosimilar development, growing adoption of digital bioprocessing tools, and a focus on cost-efficient large-scale production. Key developments foreseen in the forecast period encompass increasing adoption of single-use bioprocessing systems, rising deployment of continuous biomanufacturing, growing demand for high-volume monoclonal antibody production, expansion of modular biologics facilities, and enhanced integration of advanced process control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30212&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Biologics Manufacturing Market?

The anticipated expansion of the biologics manufacturing market is driven by the growing incidence of chronic diseases. These are enduring health conditions that progress slowly and require continuous medical oversight over an extended duration. The increased occurrence of chronic diseases stems partly from sedentary habits, where prolonged periods of sitting and minimal physical activity heighten the susceptibility to ailments like heart conditions and diabetes. Biologics manufacturing contributes to managing chronic diseases effectively through the production of targeted treatments, which are beneficial for conditions such as diabetes, cancer, and various autoimmune disorders. This process also mitigates the burden of disease by ensuring a consistent supply of superior biologic medicines, thereby enhancing patient outcomes and the efficiency of treatments. For instance, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, representing an 18% increase from 3,065,825 cases recorded in 2022. Thus, the escalating prevalence of chronic diseases is a key factor propelling the growth of the biologics manufacturing market.

What Major Segment Divisions Exist Within The Biologics Manufacturing Market?

The biologics manufacturing market covered in this report is segmented –

1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing

2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics

3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications

Subsegments:

1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems

2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production

How Are Trends Shaping The Direction Of The Biologics Manufacturing Market?

Leading companies in the biologics manufacturing market are focusing on developing advanced solutions, such as integrated biologics contract development and manufacturing organization platforms, to enhance comprehensive biologics development, improve production efficiency, and strengthen supply chain integration across various therapeutic modalities. An integrated biologics contract development and manufacturing organization (CDMO) platform represents a complete framework that combines biologics development, production, and supply services within a unified system. For instance, in June 2023, Catalent Inc., a US-based contract development and manufacturing firm, expanded its OneBio Suite for integrated development, manufacturing, and supply across diverse biologic modalities. The enhanced OneBio Suite provides a fully integrated biologics CDMO platform that supports antibodies, cell and gene therapies, and mRNA-based products. It offers end-to-end services from development through to fill-finish and packaging under a single contract and harmonized project management, which facilitates faster development timelines, improved scalability, and seamless global supply integration.

Which Companies Are Leading Innovation In The Biologics Manufacturing Market?

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

Read the full biologics manufacturing market report here:

https://www.thebusinessresearchcompany.com/report/global-biologics-manufacturing-market-report

What Are The Leading Geographic Regions In The Biologics Manufacturing Market?

North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics Manufacturing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30212&type=smp

Browse Through More Reports Similar to the Global Biologics Manufacturing Market 2026, By The Business Research Company

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795